PT-141 is the one compound here where an approved drug and the thing on sale share a molecule and almost nothing else.
An approved bremelanotide product exists in the United States. It covers one distress-defined desire disorder, in one population, and it reached approval on randomized trial evidence. That is a stronger record than most of what sells alongside it on this site.
What these sellers dispense is a compounded preparation, and it goes overwhelmingly to buyers outside that population, for reasons the approval never addressed. A vendor can say bremelanotide is approved and be telling the truth. A reader can say the vial version has no trial support for the way it is used and also be telling the truth. Both statements describe the same molecule.
That is why the evidence grade above reads as it does, and it deserves an exact reading rather than a quick one. It is not a claim that the compound is unstudied. It says the studies were run on a product, an indication and a population that the compounded market is not selling into. The research article on PT-141 works through the distinction in full.
Pricing on this board splits the way it does everywhere else here. Some sellers quote a monthly program, others quote a vial and never say how long one lasts. Each row carries the qualifier that says which it is.
What this board covers
Providers dispensing compounded PT-141 to US patients through a telehealth intake. The approved autoinjector moves through a prescriber and a pharmacy in the ordinary way and is not a telehealth price comparison. A seller offering PT-141 without a published price still appears, marked as publishing none.
No controlled human evidence
Quick picks
Top picks for pt-141
#
Provider
Score
Best for
From/mo
Visit
1
Pepti
5.0
an all-in monthly price with the supply length printed next to it, across a twelve-compound menu
$259/mo — vial price; the catalog says the supply varies by dose rather than naming a four-week quantity
Pepti is not a paid partner; this link may earn a commission if that changes. Full disclosure.
Read the pricing unit before the number. PT-141 is an on-demand product, so a vial figure and a monthly program figure can describe very different amounts of medication.
The score grades the seller. The evidence grade near the top grades the compound as it is sold here, and an approval covering a different population does not lift it.
Order is computed from declared facts and then price, so no row is positioned by hand and no commercial relationship moves one.
A blank price cell means the seller offers PT-141 and does not publish what it costs.
PT-141 providers, reviewed
1. Pepti
Pepti prints one all-in monthly figure for every treatment it sells, in two formats side by side, and it is the only roster row that publishes both a fifty-state footprint and a price for epitalon.
$259/mo — vial price; the catalog says the supply varies by dose rather than naming a four-week quantity
Strengths
Prints an all-in monthly figure on every treatment card and states that no membership fee sits on top of it
Names the unit each figure covers, so a four-week supply is never left to be guessed at
Quotes a pen and a vial price side by side, which makes the format premium visible instead of buried in checkout
States its own coverage as all 50 states and Washington, D.C. in its site footer
Trade-offs
Bloodwork is a separate charge rather than part of the monthly figure, though recent labs can be uploaded instead
The 503A/503B compounding pharmacy it uses is described but never named
The PT-141 card gives no supply length, so its figure is the only one on the catalog that cannot be read as four weeks
CJC-1295, ipamorelin and TB-500 are sold only inside combination vials
Pepti is not a paid partner; this link may earn a commission if that changes. Full disclosure.
AgelessRx publishes a short, deliberately curated peptide menu and names four compounds it has decided not to sell yet — but every headline figure on it is a first-month rate with a higher number behind it.
$199/mo — per month ongoing; the first month is $149
Strengths
Names BPC-157, TB-500, MOTS-c and KPV on its own peptide page as compounds it has chosen not to sell yet, which is rare candor in this category
Publishes the ongoing rate alongside the introductory one on three of its five peptide pages
Sells PT-141 and sermorelin in both an injection and a nasal spray rather than a single format
Says a plan can be paused or canceled at any time
Trade-offs
Every headline figure on the site is a first-month rate, and the ongoing rate runs $50 to $70 higher
The GHK-Cu cream page prints the same figure as both a first-month price and an ongoing one, so the two disagree on one page
The glutathione page gives only the three-month-plan rate, leaving the plain monthly price unpublished
The compounding pharmacy that fills prescriptions is not named, and no state list is published
A competition ranking is quoted on the site as a credential; it is marketing, not an independent assessment of the products sold
AgelessRx is not a paid partner; this link may earn a commission if that changes. Full disclosure.
Longevixx runs the widest single peptide menu on this roster — twenty programs, each quoted as a monthly figure — and it is the only seller here that lists PT-141, epitalon and semax at all.
$249/mo — starting rate, per month
Strengths
Publishes a monthly figure beside every one of its twenty peptide programs, not a starting price for the catalog as a whole
The only seller here listing PT-141, epitalon and semax, three compounds nothing else on this roster carries
Charges nothing when a request is turned down
Trade-offs
Semax, KPV, TB-500 and CJC-1295 are sold only inside combination vials, so the figure beside each is the price of a pairing rather than of that peptide alone
Its terms limit service to the states where the company operates without naming them, so coverage cannot be checked before signup
The compounding pharmacy that fills prescriptions is not named on the site
Every figure is a starting rate, and the catalog does not say what moves a program above it
Longevixx is not a paid partner; this link may earn a commission if that changes. Full disclosure.
An approval quoted without its population. The approved indication names a specific diagnosis in premenopausal women; most PT-141 marketing addresses men, and the trials behind that approval say nothing about them.
Safety information going missing along with the indication. The approved product carries a reviewed label describing effects worth knowing about, including a transient blood-pressure change and cautions for people with cardiovascular conditions. A vial arrives with none of that.
The words bremelanotide and PT-141 used interchangeably across one page. They are the same molecule and, in this market, almost never the same product.
A first-month rate presented as the price. Several sellers here publish an introductory figure prominently and the ongoing figure further down the same page.
A per-vial figure read as a monthly cost. On an on-demand compound the gap between the two can be large, and it reverses the comparison a shopper thought they were making.
How this PT-141 board is scored
Every score above comes from four yes-or-no facts, each worth an equal quarter of the total. A provider that clears all four scores 10.0; clearing none scores 0.0. Nothing else moves the number.
Names its compounding pharmacy. The pharmacy that fills the prescription is disclosed by name, not left as "our pharmacy partners."
Publishes a price. A monthly figure appears on the site itself, with its billing cycle or plan term attached.
Ships to all 50 states. Nationwide coverage, not a partial state list a shopper has to check before starting an intake.
Includes labs in the price. Baseline bloodwork is bundled into the published price rather than billed as a separate line item.
A price shown here is always the provider's own published figure for PT-141specifically, never a number carried over from something else they sell. An FDA warning letter, where one exists, is disclosed on that provider's review — it never changes this score or this position, because most letters concern marketing and labeling claims, not the contents of a vial.
Frequently asked questions
Is PT-141 FDA approved?
An approved bremelanotide product exists for one distress-defined desire disorder in premenopausal women. The PT-141 sold through the programs on this board is a compounded preparation, and compounded status is not approval.
Does the approval cover men?
No. The trials behind it enrolled premenopausal women with a specific diagnosis. Most of what is sold as PT-141 goes to men, and the approved evidence base does not extend to them.
Why is the evidence grade so low for a drug that passed trials?
The grade describes the compound as this market sells it. Bremelanotide has a real trial record for one indication in one population. For the uses PT-141 is actually bought for, that record does not apply.
How does PT-141 differ from the usual erectile-function drugs?
It acts on receptors in the brain rather than on blood flow in peripheral tissue. That makes it a different class aimed at a different part of the problem, not a stronger version of the familiar pills.
Does a paid relationship move a provider up this board?
No. Order comes from the scoring inputs printed on the board itself, with price breaking a tie. Where a commercial relationship exists it is disclosed on that row and changes nothing about its position.
What does the date beside a price mean?
It is the day that figure was last checked against the seller's own site. Prices here change quietly, so the date is printed rather than assumed.
Are any of these PT-141 providers paid partners?
None of them today. All 3 PT-141 providers on this board are compared under the same rules, whether or not a link to them ever earns a commission.
How is this board scored?
Four yes-or-no facts, printed above in full. A warning letter, where one exists, is disclosed on that provider's own review and never moves this score.
